Eurofins Scientific SE
ERFSF · Other OTC · USD
96,30USD
−3,31 (−3,32 %)Stand 10. Nov., 14:30
Kennzahlen
- Eröffnung
- 96,30
- Vortag
- 99,61
- Tagesspanne
- 96,30 – 96,30
- 52 Wochen
- 64,95 – 101,34
- Volumen
- 3
- Ø Volumen
- 2891
- Börsenwert
- 16,72 Mrd. $
- KGV
- 29,3
- Gewinn je Aktie (TTM)
- 5,11
- Dividendenrendite
- 0,8 %
- Beta
- 0,9
- Nächste Zahlen
- 28. Jan. 2027
Finanzen
| EUR | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 7,29 Mrd. | 6,95 Mrd. | 6,51 Mrd. | 6,71 Mrd. | 6,72 Mrd. |
| Herstellungskosten | 2,33 Mrd. | 2,24 Mrd. | 5,14 Mrd. | 5,2 Mrd. | 2,15 Mrd. |
| Bruttogewinn | 4,97 Mrd. | 4,71 Mrd. | 1,37 Mrd. | 1,51 Mrd. | 4,57 Mrd. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 0 | 70,19 Mio. | 135,7 Mio. | 39,4 Mio. | 60,3 Mio. |
| Operatives Ergebnis | 818,3 Mio. | 726,2 Mio. | 1,24 Mrd. | 783,2 Mio. | 1,26 Mrd. |
| EBITDA | 1,53 Mrd. | 1,56 Mrd. | 1,22 Mrd. | 1,51 Mrd. | 1,65 Mrd. |
| Nettogewinn | 474,82 Mio. | 406,4 Mio. | 310,2 Mio. | 610,2 Mio. | 782,6 Mio. |
| Gewinn je Aktie (verwässert) | 2,54 | 2,09 | 1,57 | 3,07 | 3,90 |
Bewertung
Letzte 12 Monate
- KGV
- 29,3
- Kurs-Umsatz-Verhältnis
- 2,1
- Kurs-Buchwert-Verhältnis
- 4,3
- PEG
- 1,0
- Bruttomarge
- 12,0 %
- Operative Marge
- 12,0 %
- Nettomarge
- 7,2 %
- Verschuldungsgrad
- 1,5
- EV/EBITDA
- 13,5
- Eigenkapitalrendite
- 14,8 %
- Kapitalrendite (ROIC)
- 6,8 %
- Free-Cashflow-Rendite
- 4,2 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 68,1 % | 67,8 % | 21,1 % | 22,5 % | 68,0 % |
| Operative Marge | 11,2 % | 10,4 % | 19,0 % | 11,7 % | 18,8 % |
| Nettomarge | 6,5 % | 5,8 % | 4,8 % | 9,1 % | 11,6 % |
| KGV | 23,6 | 23,8 | 37,1 | 21,3 | 27,3 |
| Kurs-Umsatz-Verhältnis | 1,5 | 1,4 | 1,8 | 1,9 | 3,2 |
| Kurs-Buchwert-Verhältnis | 3,2 | 1,8 | 2,3 | 2,7 | 4,6 |
| Verschuldungsgrad | 1,3 | 0,7 | 0,8 | 0,7 | 0,6 |
| Liquidität 3. Grades | 1,1 | 1,2 | 1,4 | 1,3 | 1,2 |
| Dividendenrendite | 1,0 % | 1,0 % | 2,0 % | 1,5 % | 0,6 % |
| Unternehmenswert | 14,87 Mrd. | 12,65 Mrd. | 14,22 Mrd. | 15,85 Mrd. | 23,63 Mrd. |
| EV/EBITDA | 9,7 | 8,1 | 11,7 | 10,5 | 14,3 |
| Eigenkapitalrendite | 13,4 % | 7,6 % | 6,1 % | 12,8 % | 16,8 % |
| Kapitalrendite (ROIC) | 6,4 % | 5,7 % | 9,6 % | 7,1 % | 12,1 % |
| Free-Cashflow-Rendite | 4,8 % | 8,2 % | 4,1 % | 3,7 % | 4,6 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +4,9 % | +6,7 % | −2,9 % | −0,1 % | +23,5 % |
| Bruttogewinn | +5,5 % | +242,8 % | −9,1 % | −66,9 % | +23,8 % |
| Operatives Ergebnis | +12,7 % | −41,4 % | +58,2 % | −37,9 % | −2,5 % |
| Nettogewinn | +16,8 % | +31,0 % | −49,2 % | −22,0 % | +45,1 % |
| Gewinn je Aktie | +21,5 % | +33,1 % | −48,9 % | −21,3 % | +41,8 % |
| Freier Cashflow | −32,3 % | +69,0 % | −1,7 % | −51,9 % | +14,1 % |
| Dividende je Aktie | +21,8 % | −57,6 % | +18,4 % | +47,3 % | +247,4 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 2Kaufen
- 1Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 7,42 Mrd. | 7,86 Mrd. | 8,34 Mrd. |
| Umsatz (Tief – Hoch) | 7,03 Mrd. – 7,58 Mrd. | 7,2 Mrd. – 8,21 Mrd. | 7,89 Mrd. – 8,51 Mrd. |
| Gewinn je Aktie (Ø) | 3,78 | 4,31 | 4,80 |
| Gewinn je Aktie (Tief – Hoch) | 3,52 – 3,88 | 4,01 – 4,42 | 4,47 – 4,93 |
| Analysten | 1 | 1 | 1 |
Quartalszahlen
Nächste Zahlen: 28. Jan. 2027| Juli 2026 | Jan. 2026 | Juli 2025 | Jan. 2025 | Juli 2024 | Feb. 2024 | Juli 2023 | März 2023 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 2,18 | 1,48 | 2,01 | 1,54 | 1,59 | 1,32 | 1,38 | 1,59 |
| Gewinn je Aktie · Tatsächlich | 2,39 | 1,50 | 1,93 | 1,39 | 1,76 | 0,95 | 1,48 | 1,46 |
| Abweichung | +9,63 % | +1,35 % | −3,98 % | −9,74 % | +10,69 % | −28,11 % | +7,25 % | −8,18 % |
| Umsatz · Tatsächlich | 4,23 Mrd. | 4,33 Mrd. | 3,96 Mrd. | 3,66 Mrd. | 3,66 Mrd. | 3,65 Mrd. | 3,5 Mrd. | 3,53 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 29. Apr. 2026 | 30. Apr. 2026 | 0,84 |
| 29. Apr. 2025 | 30. Apr. 2025 | 0,68 |
| 3. Juli 2024 | 5. Juli 2024 | 0,54 |
| 3. Juli 2023 | 6. Juli 2023 | 1,09 |
| 5. Juli 2022 | 7. Juli 2022 | 1,03 |
| 1. Juli 2021 | 5. Juli 2021 | 0,81 |
| 3. Juli 2019 | 5. Juli 2019 | 3,25 |
| 28. Juni 2018 | 2. Juli 2018 | 2,78 |
| 29. Juni 2017 | 3. Juli 2017 | 2,28 |
| 29. Juni 2016 | 1. Juli 2016 | 1,61 |
| 29. Juni 2015 | 1. Juli 2015 | 1,48 |
| 27. Juni 2014 | 2. Juli 2014 | 1,64 |
Aktiensplits
- 19. Nov. 202010:1
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Eurofins Scientific SE, along with its affiliated companies, delivers a broad spectrum of analytical testing and laboratory solutions globally. The firm utilizes an extensive repertoire of approximately 200,000 analytical techniques, designed to assess various product attributes such as safety, identification, makeup, genuineness, source, trackability, and cleanliness. Its offerings span numerous sectors. These include agro-science, encompassing biological evaluations, consumer, human, and environmental safety assessments, product chemical analysis, regulatory guidance, and seed services. The company also handles general agro testing. Its assurance division provides product inspections, audits, certifications, training, and advisory services for items across food, consumer goods, healthcare, and cosmetics industries. Other specialized areas are biopharma and clinical diagnostics. Furthermore, Eurofins conducts comprehensive consumer product testing, covering compliance, audits, examinations, certifications, inspections, training programs, and digital media and cybersecurity solutions for a diverse range of sectors. It also specializes in cosmetics and personal care product analysis, and environmental testing for substances like water, air, soil, waste, and other materials. Food and feed testing is another key segment, addressing concerns such as allergens, GMOs, grain quality, meat composition, nanomaterials, pesticides, and residual DNA. The company's extensive food-related portfolio also includes audit and certification services, authenticity verification, carbohydrate analysis, consulting, detection of dioxins and persistent organic pollutants (POPs), food irradiation checks, labeling compliance, legal guidance, heavy metal screening, identity preservation, mealtime analysis, molecular and microbiology testing, mycotoxin detection, nutritional profiling, organic contaminant analysis, packaging and migration studies, radioactivity testing, rapid testing methods, sensory and consumer research, various training initiatives, veterinary drug residue screening, and vitamin content analysis. Beyond these, Eurofins offers expertise in forensic science, genomics, maritime applications, materials and engineering, REACH compliance, and advanced technologies. The company maintains a significant global presence, operating roughly 900 laboratories across 54 nations. Established in 1987, its main office is situated in Luxembourg City, Luxembourg.
Führung
- Gilles G. MartinChairman of the Board & Chief Executive Officer
- Valerie HanoteExecutive Director
- Timothy S. OostdykExecutive Vice President of BioPharma, Genomics & Agrosciences Services North America
- Andrew SwiftHead of Investor Relations
- David W. BryantSenior Vice President of Strategic Business Development North America
- Gabriel JuliaSenior Vice President of Clinical Diagnostics Europe
- CEO
- Gilles G. Martin
- Mitarbeitende
- 65.694
- Hauptsitz
- Luxembourg City, LU, LU
- Sektor
- Healthcare
- Branche
- Medical - Diagnostics & Research
- Börsengang
- 26. Apr. 2010
- Website
- eurofins.com
Nachrichten
- Business Wire · 6. Nov., 10:31Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 3. Nov., 5:43Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 26. Okt., 11:17Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 22. Okt., 5:58Eurofins Scientific: Director/PDMR Shareholding
- Seeking Alpha · 21. Okt., 12:24Eurofins Scientific SE (ERFSF) Q3 2026 Sales/Trading Call Transcript
- Business Wire · 19. Okt., 6:00Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 14. Okt., 12:27Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 9. Okt., 5:37Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 7. Okt., 10:49Eurofins Scientific: Director/PDMR Shareholding
- Business Wire · 5. Okt., 13:38Eurofins Scientific: Director/PDMR Shareholding
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.